Rhumbline Advisers Cue Biopharma, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$1.24 - $2.18 $32,180 - $56,575	-25,952 Reduced 79.61%	6,645 $8,000
Q1 2024 May 09, 2024	BUY	$1.77 - $3.09 $1,499 - $2,617	847 Added 2.67%	32,597 $61,000
Q4 2023 Feb 08, 2024	BUY	$1.72 - $3.1 $584 - $1,054	340 Added 1.08%	31,750 $83,000
Q3 2023 Nov 09, 2023	BUY	$2.23 - $4.69 $4,500 - $9,464	2,018 Added 6.87%	31,410 $72,000
Q2 2023 Aug 08, 2023	BUY	$3.11 - $4.91 $91,409 - $144,314	29,392 New	29,392 $107,000
Q2 2022 Aug 11, 2022	SELL	$2.49 - $5.92 $79,102 - $188,066	-31,768 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$4.41 - $12.28 $158 - $442	-36 Reduced 0.11%	31,768 $155,000
Q4 2021 Feb 10, 2022	SELL	$10.86 - $17.85 $6,624 - $10,888	-610 Reduced 1.88%	31,804 $360,000
Q3 2021 Nov 12, 2021	BUY	$10.06 - $15.3 $14,084 - $21,420	1,400 Added 4.51%	32,414 $472,000
Q2 2021 Aug 05, 2021	SELL	$10.9 - $14.53 $22,650 - $30,193	-2,078 Reduced 6.28%	31,014 $361,000
Q1 2021 May 06, 2021	SELL	$11.2 - $16.09 $20,619 - $29,621	-1,841 Reduced 5.27%	33,092 $404,000
Q4 2020 Feb 10, 2021	BUY	$11.12 - $16.4 $8,562 - $12,627	770 Added 2.25%	34,933 $437,000
Q3 2020 Nov 12, 2020	SELL	$15.05 - $23.54 $26,036 - $40,724	-1,730 Reduced 4.82%	34,163 $514,000
Q2 2020 Aug 13, 2020	BUY	$12.7 - $30.73 $143,027 - $346,081	11,262 Added 45.72%	35,893 $880,000
Q1 2020 May 06, 2020	BUY	$9.85 - $22.27 $4,186 - $9,464	425 Added 1.76%	24,631 $350,000
Q4 2019 Feb 05, 2020	BUY	$7.06 - $17.47 $4,066 - $10,062	576 Added 2.44%	24,206 $384,000
Q3 2019 Oct 23, 2019	BUY	$6.78 - $9.28 $1,525 - $2,088	225 Added 0.96%	23,630 $199,000
Q2 2019 Aug 14, 2019	BUY	$7.18 - $9.65 $4,401 - $5,915	613 Added 2.69%	23,405 $210,000
Q1 2019 May 01, 2019	SELL	$4.7 - $9.29 $14 - $27	-3 Reduced 0.01%	22,792 $176,000
Q4 2018 Jan 31, 2019	BUY	$4.35 - $8.73 $33,599 - $67,430	7,724 Added 51.25%	22,795 $107,000
Q3 2018 Nov 07, 2018	SELL	$7.91 - $11.89 $6,359 - $9,559	-804 Reduced 5.06%	15,071 $136,000
Q2 2018 Aug 06, 2018	BUY	$10.93 - $14.48 $173,513 - $229,870	15,875 New	15,875 $188,000

Others Institutions Holding CUE

# of Institutions

Shares Held

14.1M

Call Options Held

14.4K

Put Options Held

2.6K

View Full List

About Cue Biopharma, Inc.

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

More about CUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account